Dendritic cells as vectors for immunotherapy of cancer

Sophie Paczesny, Hideki Ueno, Joseph Fay, Jacques Banchereau, A. Karolina Palucka

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Dendritic cells (DCs) initiate and regulate immune responses. Numerous studies in mice showed that tumor antigens-loaded DCs are able to induce therapeutic and protective anti-tumor immunity. The immunogenicity of antigens delivered on DCs has now been demonstrated in cancer patients and some clinical responses without any significant toxicity have been observed. Nevertheless, many parameters of DC vaccination need to be established including: (1) the type of DCs, their maturation stage and stimuli; (2) the quality and the breadth of induced immune responses; (3) host-related factors, such as the extent of metastatic disease and myeloablation; and (4) efficacy as measured by the clinical outcome.

Original languageEnglish (US)
Pages (from-to)439-447
Number of pages9
JournalSeminars in Cancer Biology
Volume13
Issue number6
DOIs
StatePublished - Dec 2003
Externally publishedYes

Fingerprint

Immunotherapy
Dendritic Cells
Neoplasms
Neoplasm Antigens
Immunity
Vaccination
Antigens
Therapeutics

Keywords

  • Dendritic cells
  • Immunotherapy
  • Tumor immunology
  • Vaccines

ASJC Scopus subject areas

  • Cancer Research

Cite this

Dendritic cells as vectors for immunotherapy of cancer. / Paczesny, Sophie; Ueno, Hideki; Fay, Joseph; Banchereau, Jacques; Palucka, A. Karolina.

In: Seminars in Cancer Biology, Vol. 13, No. 6, 12.2003, p. 439-447.

Research output: Contribution to journalArticle

Paczesny, Sophie ; Ueno, Hideki ; Fay, Joseph ; Banchereau, Jacques ; Palucka, A. Karolina. / Dendritic cells as vectors for immunotherapy of cancer. In: Seminars in Cancer Biology. 2003 ; Vol. 13, No. 6. pp. 439-447.
@article{b5b867670d974c1893a80a3cbfafeba1,
title = "Dendritic cells as vectors for immunotherapy of cancer",
abstract = "Dendritic cells (DCs) initiate and regulate immune responses. Numerous studies in mice showed that tumor antigens-loaded DCs are able to induce therapeutic and protective anti-tumor immunity. The immunogenicity of antigens delivered on DCs has now been demonstrated in cancer patients and some clinical responses without any significant toxicity have been observed. Nevertheless, many parameters of DC vaccination need to be established including: (1) the type of DCs, their maturation stage and stimuli; (2) the quality and the breadth of induced immune responses; (3) host-related factors, such as the extent of metastatic disease and myeloablation; and (4) efficacy as measured by the clinical outcome.",
keywords = "Dendritic cells, Immunotherapy, Tumor immunology, Vaccines",
author = "Sophie Paczesny and Hideki Ueno and Joseph Fay and Jacques Banchereau and Palucka, {A. Karolina}",
year = "2003",
month = "12",
doi = "10.1016/j.semcancer.2003.09.008",
language = "English (US)",
volume = "13",
pages = "439--447",
journal = "Seminars in Cancer Biology",
issn = "1044-579X",
publisher = "Academic Press Inc.",
number = "6",

}

TY - JOUR

T1 - Dendritic cells as vectors for immunotherapy of cancer

AU - Paczesny, Sophie

AU - Ueno, Hideki

AU - Fay, Joseph

AU - Banchereau, Jacques

AU - Palucka, A. Karolina

PY - 2003/12

Y1 - 2003/12

N2 - Dendritic cells (DCs) initiate and regulate immune responses. Numerous studies in mice showed that tumor antigens-loaded DCs are able to induce therapeutic and protective anti-tumor immunity. The immunogenicity of antigens delivered on DCs has now been demonstrated in cancer patients and some clinical responses without any significant toxicity have been observed. Nevertheless, many parameters of DC vaccination need to be established including: (1) the type of DCs, their maturation stage and stimuli; (2) the quality and the breadth of induced immune responses; (3) host-related factors, such as the extent of metastatic disease and myeloablation; and (4) efficacy as measured by the clinical outcome.

AB - Dendritic cells (DCs) initiate and regulate immune responses. Numerous studies in mice showed that tumor antigens-loaded DCs are able to induce therapeutic and protective anti-tumor immunity. The immunogenicity of antigens delivered on DCs has now been demonstrated in cancer patients and some clinical responses without any significant toxicity have been observed. Nevertheless, many parameters of DC vaccination need to be established including: (1) the type of DCs, their maturation stage and stimuli; (2) the quality and the breadth of induced immune responses; (3) host-related factors, such as the extent of metastatic disease and myeloablation; and (4) efficacy as measured by the clinical outcome.

KW - Dendritic cells

KW - Immunotherapy

KW - Tumor immunology

KW - Vaccines

UR - http://www.scopus.com/inward/record.url?scp=0742321969&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0742321969&partnerID=8YFLogxK

U2 - 10.1016/j.semcancer.2003.09.008

DO - 10.1016/j.semcancer.2003.09.008

M3 - Article

VL - 13

SP - 439

EP - 447

JO - Seminars in Cancer Biology

JF - Seminars in Cancer Biology

SN - 1044-579X

IS - 6

ER -